Characterized by the presence of malignant cells in the tissues of the prostate, prostate cancer (PCa) is the fourth most frequent cancer in the world and the second most frequent cancer among men.1 Statistically, one in every 350 men under the age of 50 will experience PCa, with incidences increasing in every 10-year age gap (i.e., one in every 52 men for ages 50 to 59 years). Additionally, the incidence rate is nearly 60% in men over the age of 65 years.2
While age plays a major factor, other risk factors for PCa include obesity, a saturated fat-rich diet, high testosterone levels, or family history.3 If diagnosed, reports indicate that the five-year survival rate for the majority with local or regional PCa is nearly 100%, and the five-year survival rate in those with metastatic PCa drops to 30%.4 Roughly half of the men developing PCa will see the cancer progress to metastatic.5
Since 2016, biopharma companies have initiated over 800 ongoing clinical trials in PCa, with the Asia Pacific region involved in approximately 35% of the trials. Access this report to better understand the incidence, distribution, and possible control of PCa in the Asia Pacific region, the standard of care, the trial landscape, and more.